SBI Securities’s TransCode Therapeutics RNAZ Stock Holding History

SBI Securities’s Portfolio RNAZ Stock Details RNAZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$75	Hold	12	–	–	﹤0.01%	3576
2026 Q1	$103	Buy	12 +2	+20%	+$19	﹤0.01%	3398
2025 Q4	$68	Hold	10	–	–	﹤0.01%	3519
2025 Q3	$108	Hold	10	–	–	﹤0.01%	3492
2025 Q2	$78	Sell	10 -3	-23%	-$28	﹤0.01%	3610
2025 Q1	$185	Buy	+13	New	+$1.67K	﹤0.01%	3248

SBI Securities's RNAZ Position: Q2 2026 in Review

SBI Securities held its TransCode Therapeutics (RNAZ) position steady in Q2 2026 at 12 shares worth $75. The position accounts for ﹤0.01% of the portfolio, ranked #3576.

SBI Securities first reported a position in RNAZ in Q1 2025 and has held it in 6 quarters since. The position peaked at $185 in Q1 2025. 1 fund tracked by Wall St. Rank holds RNAZ as of Q2 2026.

SBI Securities held 12 shares of TransCode Therapeutics worth $75 as of Q2 2026.
SBI Securities left its TransCode Therapeutics share count unchanged in Q2 2026.
TransCode Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3576 holding.
SBI Securities first reported a position in TransCode Therapeutics in Q1 2025 and has held it in 6 quarters since.
SBI Securities's TransCode Therapeutics position peaked at $185 in Q1 2025.
1 fund tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.